ClinicalTrials.gg
Not yet recruitingNCT07334496Updated Jan 12, 2026

A Study to Evaluate the Biosimilarity of GLR1044 Injection and Dupilumab Injection (Dupixent®) in Healthy Adult Male Subjects

A Phase 1 interventional study of GLR1044 injection and Dupilumab Injection in Biosimilarity, sponsored by Gan & Lee Pharmaceuticals.. Not yet recruiting at 1 site in China. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-12.

Sponsored by Gan & Lee Pharmaceuticals. · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
198
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

This is a randomized, double-blind, single-dose, parallel comparison biosimilarity study conducted in healthy Chinese adult male subjects.

It is planned to enroll 198 male subjects in this study. Eligible subjects will be randomized into 2 dosing groups at 1:1 (GLR1044 group or Dupilumab group), i.e., 99 subjects in each group. Each subject is administered once by subcutaneous injection in the abdomen, during which the subject is required to be hospitalized for 4 days. The safety follow-up will last until D57.

02

Conditions studied

  • Biosimilarity

Keywords

  • Biosimilarity
03

In context

Lead sponsor

Gan & Lee Pharmaceuticals. is the lead sponsor of 30 studies on the registry; 15 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1.Voluntarily sign the form (ICF) before the study, fully understand the contents, process and possible adverse reactions of the study, and be able to follow the and restrictions specified in this protocol.

    2. Male subjects aged 18 to 55 years (both inclusive) at the time of signing informed consent forms.

    3. Subjects must agree to use reliable for themselves and their partners during the study and within 6 months after the end of the study (the contraception used should comply with local regulations on the use of contraceptive methods for subjects participating in clinical studies), and not donate sperm for assisted reproductive purposes.

    4. The (BMI) at screening is 19-26 kg/m2 (both exclusive), and the weight is 55-85 kg (both exclusive).

    5. The results of medical history review, physical examinations, laboratory tests, imaging examinations and at screening/visit 2 (V2) are judged by the investigator to be normal or abnormal but not .

No personal history of tuberculosis, no possible previous history of tuberculosis exposure, and no previous and/or current immunomodulatory treatment.

6.No personal history of tuberculosis, no possible previous history of tuberculosis exposure, and no previous and/or current immunomodulatory treatment.

Exclusion criteria

Exclusion Criteria:

  • 1.History of drug abuse within 1 year prior to screening, or positive predose drug abuse screening result at Visit 2 (V2); or history of alcohol abuse within 6 months prior to screening, or positive predose alcohol breath test result at V2.

    2. Subjects who smoked > 5 cigarettes/day within 3 months prior to screening or who cannot stop using any tobacco products during the study.

    3. The subject and/or first-degree relatives have a history of venous thromboembolic events or idiopathic venous thromboembolic events before screening.

    4. Presence of sunburn, scar tissue, tattoos, open ulcers or branding at screening that the investigator believes will interfere with the interpretation of adverse skin reactions.

    5. Eye or oral infections at screening, including but not limited to conjunctivitis, blepharitis and oral herpes.

    6. The following medical history with a clear diagnosis in the past or at screening: Subjects with cardiovascular disorders, hematological diseases, respiratory disorders, digestive system diseases, abnormal hepatic function, abnormal renal function, endocrine and metabolic disorders (except for overweight), nervous system disorders or psychiatric disorders, skin and subcutaneous tissue disorders, musculoskeletal system disorders, and immune system disorders, who in the opinion of the investigator should be excluded from the study due to the above-mentioned diseases, or other diseases that may interfere with the interpretation of study results.

    7. The estimated at screening is \< 90 mL/min/1.73m2 as calculated using the CKD-EPI equation.

    8. Any malignant tumor suspected or diagnosed prior to screening. 9. Subjects with blood donation or blood loss ≥ 400 mL within 3 months prior to screening, or subjects with bone marrow donation.

    10. Subjects who have undergone major surgery (including but not limited to surgery requiring general anesthesia) or organ transplantation within 3 months prior to screening, or are still in a state of illness, trauma or incomplete recovery from surgery at the time of screening (e.g., significant impairment in daily living or working capacity compared to pre-illness/injury/surgery status), or plan to undergo surgery during the study or within two months after the end of the study.

    11.Subjects with allergic constitution, or a history of allergic diseases such as bronchial asthma, urticaria, and eczema.

    12. Known or suspected intolerance or to any biological drug and its , or known allergy or reaction to murine-derived, chimeric, or humanized proteins in monoclonal antibodies or antibody fragments.

    13. Subjects who tested positive for (HIV) antigen antibody, treponema pallidum antibody, surface antigen (HBsAg) quantitative assay, hepatitis B core antibody (HBcAb), or virus (HCV) antibody at screening.

    14.Use of Dupilumab Injection and other cytokine (including but not limited to tumor necrosis factor, interleukin, etc.) targeted agents before screening, or use of other drugs that may affect the judgment of this study result within 3 months before screening (including but not limited to Janus kinase (JAK) inhibitor, phosphodiesterase-4 inhibitor, Fc receptor antagonists (Rozanolixizumab, Efgartigimod, etc.), any biological drugs and preparations, etc.); or have used any biological agent containing immunoglobulins within 1 year before screening.

    15.Subjects who have participated in any clinical trial of an unmarketed drug or vaccine and received medication within 3 months before screening or within 5 half-lives of the previous medicinal product (whichever is longer), or subjects who plan to be vaccinated during the study period or within 2 months after the end of the study.

    16. Subjects who have used prescription and over-the-counter (OTC) drugs, herbal medicines, traditional Chinese medicines, and Chinese patent medicines without the approval of the investigator within 14 days before administration at Visit 2 (V2).

    17. Those who are investigators or employees of the study site, or family members of the employees or investigators.

    18. The investigator believes that there is any condition that may cause the subject to be unable to complete this study or bring obvious risks to the subject, or other investigators believe that the subject has any condition that makes him/her unsuitable for participating in this study, or the subject may not be able to complete this clinical trial for other reasons.

Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
198 participants (estimated)

Study arms

  • Experimental
    GLR1044 injection

    Drug: GLR1044 injection

  • Active comparator
    Dupilumab Injection

    Drug: Dupilumab Injection

Interventions

  • DrugGLR1044 injection

    GLR1044 injection 300mg/2.0mL; subcutaneous injection; single dose

  • Dupilumab Injection 300mg/2.0mL; subcutaneous injection; single dose

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic indicators:Cmax

    Time frame: Day 1-Day 57

  2. Pharmacokinetic indicators:AUC0-∞.

    Time frame: Day 1-Day 57

Secondary outcomes

  1. Pharmacokinetic indicators: AUC0-t

    Time frame: Day 1-Day 57

  2. Pharmacokinetic indicators: CL

    Time frame: Day 1-Day 57

  3. Pharmacokinetic indicators: λz

    Time frame: Day 1-Day 57

  4. Pharmacokinetic indicators: Tmax

    Time frame: Day 1-Day 57

  5. Pharmacokinetic indicators: t1/2

    Time frame: Day 1-Day 57

  6. Pharmacokinetic indicators: Vz

    Time frame: Day 1-Day 57

  7. Pharmacokinetic indicators: MRT

    Time frame: Day 1-Day 57

  8. Pharmacokinetic indicators: AUC0-t/AUC0-∞ ratio.

    Time frame: Day 1-Day 57

  9. Safety: Number of treatment-emergent adverse events (TEAEs)

    Time frame: Day 1-Day 57

  10. Safety: Number of treatment-emergent serious adverse events (TESAEs).

    Time frame: Day 1-Day 57

  11. Immunogenicity: Anti-drug antibody (ADA)

    Time frame: Day 1-Day 57

  12. Immunogenicity: neutralizing antibody (NAb)

    Time frame: Day 1-Day 57

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2026; primary completion for Jul 2026, 4 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2025
First posted
Jan 12, 2026
StartEst.
Mar 9, 2026
Primary completionEst.
Jul 17, 2026
CompletionEst.
Jul 17, 2026
Last update
Jan 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07334496
Responsible party
Sponsor
First posted
Jan 12, 2026
Start date
Mar 9, 2026 (estimated)
Primary completion
Jul 17, 2026 (estimated)
Completion
Jul 17, 2026 (estimated)
Last update
Jan 12, 2026

Study contacts

jianpeng su
Contact
jianpeng.su@ganlee.com
+8615829644383

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion